Commission Regulation (EC) No 508/1999 of 4 March 1999 amending Annexes I to IV to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin
Changes over time for: ANNEX III
Status:
Point in time view as at 31/12/2020.
Changes to legislation:
There are currently no known outstanding effects for the Commission Regulation (EC) No 508/1999, ANNEX III.![Help about Changes to Legislation](/images/chrome/helpIcon.gif)
![Close](/images/chrome/closeIcon.gif)
Changes to Legislation
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
ANNEX IIIU.K.LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES USED IN VETERINARY MEDICINAL PRODUCTS FOR WHICH PROVISIONAL MAXIMUM RESIDUE LIMITS HAVE BEEN FIXED
1.Anti-infectious agentsU.K.
1.1.ChemotheurapeuticsU.K.
1.1.2.BenzenesulphonamidesU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Clorsulon | Clorsulon | Bovine | 50 μg/kg | Muscle | Provisional MRLs expire on 1 January 2000 |
| | | 150 μg/kg | Liver | |
| | | 400 μg/kg | Kidney | |
1.2.AntibioticsU.K.
1.2.1.Beta-lactamase inhibitorsU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Clavulanic acid | Clavulanic acid | Bovine, ovine | 200 μg/kg | Milk | Provisional MRLs expire on 1 July 1999 |
| | Bovine, ovine, porcine | 200 μg/kg | Muscle | |
| | | 200 μg/kg | Fat | |
| | | 200 μg/kg | Liver | |
| | | 200 μg/kg | Kidney | |
1.2.2.MacrolidesU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Erythromycin | MRLs apply to all microbiological active residues expressed as erythromycin equivalent | Bovine, ovine | 40 μg/kg | Milk | Provisional MRLs expire on 1 June 2000 |
| | Bovine, ovine, porcine, poultry | 400 μg/kg | Muscle | |
| | | 400 μg/kg | Fat | |
| | | 400 μg/kg | Liver | |
| | | 400 μg/kg | Kidney | |
| | Poultry | 200 μg/kg | Eggs | |
Josamycin | Josamycin | Chicken | 200 μg/kg | Muscle | Provisional MRLs expire on 1 July 2000 |
| | | 200 μg/kg | Fat | |
| | | 200 μg/kg | Liver | |
| | | 400 μg/kg | Kidney | |
| | | 200 μg/kg | Eggs | |
1.2.5.AminoglycosidesU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Aminosidine | Aminosidine | Bovine, porcine, rabbits, chicken | 500 μg/kg | Muscle | Provisional MRLs expire on 1 July 2000 |
| | | 1 500 μg/kg | Liver | |
| | | 1 500 μg/kg | Kidney | |
Apramycin | Apramycin | Bovine | 1 000 μg/kg | Muscle | Provisional MRLs expire on 1 July 1999 |
| | For use in non-lactating cattle only | 1 000 μg/kg | Fat | |
| | | 10 000 μg/kg | Liver | |
| | | 20 000 μg/kg | Kidney | |
| | Porcine | 1 000 μg/kg | Muscle | |
| | | 1 000 μg/kg | Skin and fat | |
| | | 1 000 μg/kg | Liver | |
| | | 5 000 μg/kg | Kidney | |
Dihydrostreptomycin | Dihydrostreptomycin | Bovine, ovine | 200 μg/kg | Milk | Provisional MRLs expire on 1 June 2000 |
| | Bovine, ovine, porcine, poultry | 500 μg/kg | Muscle | |
| | | 500 μg/kg | Fat | |
| | | 500 μg/kg | Liver | |
| | | 1 000 μg/kg | Kidney | |
Gentamicin | Gentamicin | Bovine | 100 μg/kg | Milk | Provisional MRLs expire on 1 June 2000 |
| | Bovine, porcine | 100 μg/kg | Muscle | |
| | | 100 μg/kg | Fat | |
| | | 200 μg/kg | Liver | |
| | | 1 000 μg/kg | Kidney | |
Neomycin (including framycetin) | Neomycin | Bovine, ovine, caprine | 500 μg/kg | Milk | Provisional MRLs expire on 1 June 2000 |
| | Bovine, ovine, caprine, porcine, chicken, turkey, duck | 500 μg/kg | Muscle | |
| | | 500 μg/kg | Fat | |
| | | 500 μg/kg | Liver | |
| | | 5 000 μg/kg | Kidney | |
| | Chicken | 500 μg/kg | Eggs | |
Spectinomycin | Spectinomycin | Bovine | 200 μg/kg | Milk | Provisional MRLs expire on 1 July 2000 |
| | Bovine, porcine, poultry | 300 μg/kg | Muscle | |
| | | 500 μg/kg | Fat | |
| | | 2 000 μg/kg | Liver | |
| | | 5 000 μg/kg | Kidney | |
Streptomycin | Streptomycin | Bovine, ovine | 200 μg/kg | Milk | Provisional MRLs expire on 1 June 2000 |
| | Bovine, ovine, porcine, poultry | 500 μg/kg | Muscle | |
| | | 500 μg/kg | Fat | |
| | | 500 μg/kg | Liver | |
| | | 1 000 μg/kg | Kidney | |
1.2.6.QuinolonesU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Decoquinate | Decoquinate | Bovine, ovine | 500 μg/kg | Muscle | Provisional MRLs expire on 1 July 2000 |
| | | 500 μg/kg | Fat | |
| | | 500 μg/kg | Liver | |
| | | 500 μg/kg | Kidney | |
Enrofloxacin | Sum of enrofloxacin and ciprofloxacin | Ovine | 100 μg/kg | Muscle | Provisional MRLs expire on 1 July 1999 |
| | | 100 μg/kg | Fat | |
| | | 300 μg/kg | Liver | |
| | | 200 μg/kg | Kidney | |
Flumequine | Flumequine | Bovine, ovine, porcine, chicken | 50 μg/kg | Muscle | Provisional MRLs expire on 1 January 2000 |
| | | 50 μg/kg | Fat or skin and fat | |
| | | 100 μg/kg | Liver | |
| | | 300 μg/kg | Kidney | |
| | Salmonidae | 150 μg/kg | Muscle and skin | |
Marbofloxacin | Marbofloxacin | Bovine | 150 μg/kg | Muscle | Provisional MRLs expire on 1 July 2000 |
| | | 50 μg/kg | Fat | |
| | | 150 μg/kg | Liver | |
| | | 150 μg/kg | Kidney | |
| | | 75 μg/kg | Milk | |
| | Porcine | 150 μg/kg | Muscle | |
| | | 50 μg/kg | Skin and fat | |
| | | 150 μg/kg | Liver | |
| | | 150 μg/kg | Kidney | |
1.2.9.PolymyxinsU.K.
Phamarcologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Colistin | Colistin | Bovine, ovine | 50 μg/kg | Milk | Provisional MRLs expire on 1 July 2000 |
| | Bovine, ovine, porcine, chicken, rabbits | 150 μg/kg | Muscle | |
| | | 150 μg/kg | Fat | |
| | | 150 μg/kg | Liver | |
| | | 200 μg/kg | Kidney | |
| | Chicken | 300 μg/kg | Eggs | |
1.2.10.PenicillinsU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Penethamate | Benzylpenicillin | Ovine | 50 μg/kg | Muscle | Provisional MRLs expire on 1 January 2000 |
| | | 50 μg/kg | Fat | |
| | | 50 μg/kg | Liver | |
| | | 50 μg/kg | Kidney | |
| | | 4 μg/kg | Milk | |
| | Porcine | 50 μg/kg | Muscle | |
| | | 50 μg/kg | Fat | |
| | | 50 μg/kg | Liver | |
| | | 50 μg/kg | Kidney | |
1.2.11.Florfenicol and related compoundsU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Florfenicol | Sum of florfenicol and its metabolites measured as florfenicol-amine | Fish | 1 000 μg/kg | Muscle and skin in natural proportions | Provisional MRLs expire on 1 July 2001 |
2.Antiparasitic agentsU.K.
2.1.Agents acting against endoparasitesU.K.
2.1.2.Benzimidazoles and pro-benzimidazolesU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Albendazole sulphoxide | Sum of albendazole, albendazole sulphoxide, albendazole sulphone, and albendazole 2-amino sulphone, expressed as albendazole | Bovine, ovine | 100 μg/kg | Milk | Provisional MRLs expire on 1 January 2000 |
| | Bovine, ovine, pheasant | 100 μg/kg | Muscle | |
| | | 100 μg/kg | Fat | |
| | | 1 000 μg/kg | Liver | |
| | | 500 μg/kg | Kidney | |
Netobimin | Sum of netobimin and albendazole and metabolites of albendazole measured as 2-amino- benzimidazole sulphone | Bovine, ovine, caprine | 100 μg/kg | Muscle | Provisional MRLs expire on 31 July 1999 |
| | | 100 μg/kg | Fat | |
| | | 1 000 μg/kg | Liver | |
| | | 500 μg/kg | Kidney | |
| | | 100 μg/kg | Milk | |
2.2.Agents acting against ectoparasitesU.K.
2.2.1.FormamidinesU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Amitraz | Sum of amitraz and all metabolites containing the 2,4-DMA moeity, expressed as amitraz | Bees | 200 μg/kg | Honey | Provisional MRLs expire on 1 July 1999 |
2.2.2.Iminophenyl thiazolidine derivativeU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Cymiazole | Cymiazole | Bees | 1 000 μg/kg | Honey | Provisional MRLs expire on 1 July 1999 |
2.2.3.Pyretrin and pyrethroidsU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Cyfluthrin | Cyfluthrin | Bovine | 10 μg/kg | Muscle | Provisional MRLs expire on 1 January 2001 |
| | | 50 μg/kg | Fat | |
| | | 10 μg/kg | Liver | |
| | | 10 μg/kg | Kidney | |
| | | 20 μg/kg | Milk | |
| | | | Further provisions in Council Directive 94/29/EC are to be observed (OJ L 189, 23.7.1994, p. 67) | |
2.2.4.OrganophosphatesU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Azamethiphos | Azamethiphos | Salmonidae | 100 μg/kg | Muscle and skin in natural proportions | Provisional MRLs expire on 1 June 1999 |
2.2.5.Acyl urea derivatesU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Teflubenzuron | Teflubenzuron | Salmonidae | 500 μg/kg | Muscle and skin in natural proportions | Provisional MRLs expire on 1 July 1999 |
2.3.Agents acting against endo- and ectoparasitesU.K.
2.3.1.AvermectinsU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Moxidectin | Moxidectin | Equidae | 50 μg/kg | Muscle | Provisional MRLs expire on 1 January 2000 |
| | | 500 μg/kg | Fat | |
| | | 100 μg/kg | Liver | |
| | | 50 μg/kg | Kidney | |
3.Agents acting on the nervous systemU.K.
3.2.Agents acting on the autonomic nervous systemU.K.
3.2.1.β 2 sympathomimetic agentsU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Clenbuterol hydrochloride | Clenbuterol | Bovine | 0,1 μg/kg | Muscle | Provisional MRLs expire on 1 July 2000 |
| | Indication: solely for tocolysis in parturient cows | 0,5 μg/kg | Liver | |
| | | 0,5 μg/kg | Kidney | |
| | | 0,05 μg/kg | Milk | |
| | Equidae | 0,1 μg/kg | Muscle | |
| | Indications: tocolysis and the treatment of respiratory ailments | 0,5 μg/kg | Liver | |
| | | 0,5 μg/kg | Kidney | |
5.Anti-inflammatory agentsU.K.
5.1.Nonsteroidal anti-inflammatory agentsU.K.
5.1.1.Arylpropionic acid derivativeU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Carprofen | Carprofen | Bovine | 500 μg/kg | Muscle | Provisional MRLs expire on 1 January 2000 |
| | | 500 μg/kg | Fat | |
| | | 1 000 μg/kg | Liver | |
| | | 1 000 μg/kg | Kidney | |
| | Equidae | 50 μg/kg | Muscle | |
| | | 100 μg/kg | Fat | |
| | | 1 000 μg/kg | Liver | |
| | | 1 000 μg/kg | Kidney | |
5.1.2.Enolic acid derivatesU.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|
Meloxicam | Meloxicam | Bovine | 25 μg/kg | Muscle | Provisional MRLs expire on 1 January 2000 |
| | | 60 μg/kg | Liver | |
| | | 35 μg/kg | Kidney | |
Yn ôl i’r brig